Laura Shawver (Silverback Therapeutics)

Fol­low­ing a hefty Se­ries B, Sil­ver­back Ther­a­peu­tics quick­ly pulls in $85M for 'an im­por­tant growth phase'

Months af­ter reel­ing in a $78 mil­lion Se­ries B round, Sil­ver­back Ther­a­peu­tics has hooked an even larg­er Se­ries C.

The Seat­tle-based com­pa­ny an­nounced Wednes­day that it net­ted $85 mil­lion from a slate of new and pre­vi­ous in­vestors. The quick boost could be a sign that an IPO is on the way.

In an email, Sil­ver­back CEO Lau­ra Shawver told me she was “not able to pro­vide any ad­di­tion­al com­ments about Sil­ver­back” be­yond what was shared in the com­pa­ny’s news re­lease. In the pre­pared state­ment, she said the com­pa­ny is at “an im­por­tant growth phase.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.